Sign in
Not yet recruitingNo phase

Two light-based treatments for painful erosive oral lichen planus compared

Compares two light treatments in adults with erosive oral lichen planus.

Key facts

Who runs it
Alexandria University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Curcumin-mediated Photodynamic Therapy Versus Photobiomodulation in the Treatment of Oral Erosive Lichen Planus
Status
Not yet recruiting
People taking part
42 people, planned
Started
30 Sept 2026
Expected to end
15 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nano- Curcumin-Mediated Photodynamic Therapy (PDT)
  • Photobiomodulation Therapy (PBM)
Record updated
2 November 2026

Who can take part

The trial is looking for adults with painful erosive oral lichen planus that has not improved with usual treatment. It compares curcumin gel with light therapy (PDT) against low-level light therapy (PBM).

Age
18 Years to 65 Years
Sex
All sexes can join.
Disease stage
Erosive oral lichen planus, confirmed by exam and tissue sample (biopsy), without abnormal pre-cancer cell changes (dysplasia) by WHO criteria. Not helped by conventional treatment. Painful sores with a pain score of at least 4 on a standard Numerical Rating Scale (NRS).
Earlier treatment
Must have had conventional treatment that did not work. Must have stopped all local or whole-body corticosteroid or immune-suppressing medicines for at least 4 weeks before the start.
Main reasons for not taking part
  • Pregnant or breastfeeding women
  • Smokers, poor mouth hygiene or severe gum disease
  • Other autoimmune diseases, or lichen planus outside the mouth
  • Lichen-like reactions caused by amalgam fillings or medicines; light-sensitivity conditions or light-sensitizing medicines
  • Diabetes, high blood pressure, heart disease or a pacemaker
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Patients diagnosed clinically and histopathologically with erosive oral lichen planus without dysplastic features based on WHO criteria
  • Patients diagnosed with oral erosive lichen planus refractory to conventional treatment
  • Patients complaining of painful lesions with pain threshold at a minimum value of 4 on a standard Numerical Rating Scale (NRS)
  • Therapeutic Washout: Absolute suspension of all localized or systemic corticosteroid / immunosuppressive regimens for at least 4 weeks prior to structural baseline evaluations

Who cannot take part

  • Presence of secondary concurrent multi-system autoimmune pathologies
  • Lichenoid reactions: Lesions exhibiting definitive spatial localization to dental amalgam margins or secondary to active drug induction
  • Diagnosed systemic photosensitivity syndromes or secondary utilization of systemic photosensitizing therapeutic agents
  • Bad oral hygiene , severe periodontal disease
  • Underlying systemic diseases like diabetes , hypertension , cardiac patients , pace makers
  • Pregnant or lactating females due to lack of standard safety parameters
  • Smokers
  • Patients with extra oral manifestations

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Oral lichen planus

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background: Oral Lichen Planus (OLP) is a chronic, T-cell-mediated inflammatory disease of the oral mucosa, with the erosive form causing painful ulcerations and erosions, significantly impacting the patient's quality of life and carrying a risk of malignant transformation. While corticosteroids remain the first-line treatment, their long-term use is limited by significant local and systemic side effects. Consequently, there is a critical need for effective, non-invasive and safe alternative therapies. Photodynamic Therapy (PDT) and Photobiomodulation (PBM) have emerged as promising light-based modalities. Curcumin, a natural polyphenol, has gained attention as a safe and effective photosensitizer for PDT due to its anti-inflammatory and antioxidant properties.

Read full original descriptionShow less

Aim: This clinical trial aims to evaluate and compare the effect of nano-curcumin formulation incorporated into biodegradable mucoadhesive gel as a photosensitizer for Photodynamic Therapy (PDT) versus Photobiomodulation (PBM) in the treatment of oral erosive lichen planus.

The 2 groups in the trial

  • Test GroupTreatment being tested

    Treatment: Nano- Curcumin-Mediated Photodynamic Therapy (PDT)

  • Control GroupExisting treatment, for comparison

    Treatment: Photobiomodulation Therapy (PBM)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Curcumin-mediated Photodynamic Therapy Versus Photobiomodulation in the Treatment of Oral Erosive Lichen Planus (a Randomized Clinical Trial)
Plain-language title
Two light-based treatments for painful erosive oral lichen planus comparedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07910175, who can take part
Record updated
2 November 2026